Related Experiment Video
Updated: Aug 11, 2025
Evaluating Cell Death Signaling by Immunofluorescence in a Rat Model of Ischemic Stroke
Published on: January 3, 2025
The prognostic value of caveolin-1 levels in ischemic stroke patients after mechanical thrombectomy
Qingguang Wang1, Haiming Cao2, Yan E2
1Department of Neurology, Jiangyin Hospital Affiliated to Nantong University, Jiangyin, 214400, Jiangsu, China.
Insights
Higher serum caveolin-1 (Cav-1) levels in patients undergoing mechanical thrombectomy (MT) for ischemic stroke are linked to better 3-month functional outcomes. Cav-1 may serve as a prognostic biomarker for stroke recovery after reperfusion therapy.
Area of Science:
- Neurology
- Biomarkers
- Stroke Research
Background:
- The prognostic value of serum caveolin-1 (Cav-1) after mechanical thrombectomy (MT) for ischemic stroke remains largely undetermined.
- Understanding factors influencing post-stroke outcomes is crucial for optimizing patient care.
Purpose of the Study:
- To investigate the association between serum Cav-1 levels and 3-month functional outcomes in patients who underwent MT.
- To determine if Cav-1 can serve as a predictive biomarker in ischemic stroke patients.
Main Methods:
- Prospective enrollment of patients with anterior circulation large vessel occlusion undergoing MT.
- Measurement of serum Cav-1 concentrations post-admission.
- Assessment of 90-day functional outcome using the modified Rankin Scale (mRS).
Main Results:
- A total of 237 patients were analyzed; 55.3% experienced a poor 90-day outcome.
- Elevated serum Cav-1 levels were significantly associated with a reduced risk of poor 90-day outcome (OR, 0.59; P=0.013) after covariate adjustment.
- A linear association was observed between Cav-1 levels and improved functional outcomes.
Conclusions:
- Increased serum Cav-1 levels correlate with improved 3-month prognosis in ischemic stroke patients treated with MT.
- Serum Cav-1 shows potential as a prognostic biomarker for predicting recovery after reperfusion therapy for ischemic stroke.
Background And Purpose:
The impact of serum caveolin-1 (Cav-1) on clinical outcomes in patients after mechanical thrombectomy (MT) is unclear. We aimed to investigate the association between serum cav-1 levels and the 3-month functional outcome.
Methods:
We prospectively enrolled and analyzed patients with an anterior circulation large vessel occlusion who underwent MT. Serum cav-1 concentrations were tested after admission. The primary outcome was a 90-day modified Rankin Scale score of 3-6.
Results:
Of the 237 recruited patients (mean age, 69.7 ± 12.1 years; 152 male), 131 (55.3%) experienced a 90-day poor outcome. After adjustment for demographic characteristics and other covariates, patients with higher serum Cav-1 levels had a reduced risk of poor outcome at 3 months (Per 1-standard deviation increase; odd ratios [OR], 0.59; 95% confidence interval [CI], 0.39 - 0.89, P = 0.013). Elevated Cav-1 concentrations (Per 1-standard deviation increase; OR, 0.59; 95% CI, 0.40 - 0.88, P = 0.011) were significantly associated with a favorable shift in modified Rankin Scale score distribution. Similar results were confirmed when the Cav-1 levels were analyzed as a categorical variable. Furthermore, the restricted cubic spline showed a linear association between Cav-1 levels and 90-day poor outcome (P = 0.032 for linearity).
Conclusions:
Increased serum Cav-1 levels were associated with improved prognosis at 3 months in ischemic stroke patients after MT, suggesting that Cav-1 may be a potential prognostic biomarker for ischemic stroke after reperfusion therapy.
